RxDoctor Payments Data

Alexis Charbonneau, NP

Nurse Practitioner · Boonville, NYNPI 1922791425

Payments from drug & device makers

$737in general payments, 2019–2025

Across 35 payments — averaging $21.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$106
  • Grifols USA, LLC$102
  • Lilly USA, LLC$86
  • AstraZeneca$76
  • GSK$70
  • Pfizer$62
  • plus $237 from 8 others

What the payments were for

  • Food & beverage$737100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$737 in reported general payments places this provider in the 85th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$21,366
Medicare patients
96
Services billed
352

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide91$96,530
EliquisApixaban65$52,038
TrulicityDulaglutide20$33,781
XareltoRivaroxaban20$31,791
FarxigaDapagliflozin Propanediol22$30,872
JardianceEmpagliflozin21$27,893
JanuviaSitagliptin Phosphate11$18,738
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$17,146
VascepaIcosapent Ethyl11$11,386
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$8,210
Breo ElliptaFluticasone/Vilanterol20$7,674
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$7,606
Incruse ElliptaUmeclidinium Bromide13$5,221
Albuterol Sulfate HfaAlbuterol Sulfate73$2,506
Irbesartan46$2,461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$106$96,53091 claims
PfizerEliquis$62$52,03865 claims
AstraZenecaFarxiga, Breztri Aerosphere$76$39,08233 claims
Boehringer IngelheimJardiance, Stiolto Respimat$15$35,49935 claims
Lilly USA, LLCTrulicity$86$33,78120 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$70$30,04154 claims
AbbVieSynthroid$18$2,00626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in Boonville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →